# Low EBI3 Expression Promotes the Malignant Degree of Gastric Cancer

## TL;DR

Low EBI3 levels in gastric cancer tissues are linked to more aggressive cancer behavior and worse patient outcomes.

## Contribution

This study identifies EBI3 as a potential prognostic marker and therapeutic target in gastric cancer.

## Key findings

- Low EBI3 expression correlates with advanced TNM stage and poor prognosis in gastric cancer patients.
- Overexpression of EBI3 reduces cancer cell proliferation, migration, and tumorigenicity in BGC-823 cells.
- Downregulation of EBI3 increases the malignant behavior of gastric cancer cells.

## Abstract

To explore expression changes and clinical significance of EBI3 in gastric cancer.

Expression of EBI3 in gastric cancer (GC) cell lines, GC tissues, and corresponding adjacent tissues were detected by qRT-PCR, Western blot, or immunohistochemistry. The relationship between the EBI3 expression and clinicopathological features of GC patients was analyzed. Expression of EBI3 in BGC-823 was overexpressed or downregulated, then, the changes of proliferation, migration, invasion, and tumorigenicity of BGC-823 were observed by MTT, scratch test, Transwell test, and tumorigenesis assay model.

EBI3 was lowly expressed in GC tissues. EBI3 expression in BGC823 was highest than other cell lines. EBI3 expression was significantly associated with TNM stage. GC patients with low expression of EBI3 had a rather poor prognosis than the GC patients with high expression of EBI3. Low EBI3 expression was an independent risk predictor of the prognosis of GC patients. After EBI3 was overexpressed, the viability, migration, invasion, and tumorigenicity abilities of BGC-823 were significantly reduced. Opposite effect was observed after EBI3 expression was downregulated.

EBI3 low expression is closely related to the malignant degree of GC and may be a predictive indicator of the prognosis of GC and potential therapeutic targets.